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high risk to be non compliant. Patients declaring good compli-
ance, aged <77.5, with a good patient-clinician relationship were
likely to be compliant. CONCLUSIONS: When medical data
were not associated with compliance, patient reported outcome
might help at identifying glaucoma treatment compliance issues.
Treatment compliance is a complex concept, including several
dimensions with interactions. EDSQ demonstrated some abilities
at identifying non compliant patients. Age, declared compliance
and satisfaction with patient-clinician relationship are dimen-
sions that would be worth being explored before switching a
glaucoma treatment due to lack of intra-ocular pressure control.
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OBJECTIVES: It has long been suspected that treatment compli-
ance is affected by HRQoL. The aim of this study is to assess how
compliance is related to GSS scores and other treatment variables
in Glaucoma. METHODS: An observational study was carried
out gathering information on the Spanish version of the Glau-
coma Symptom Scale (GSS), three compliance scales (Morisky-
Green, Haynes-Sackett, & Batalla) and information about
disease severity and treatment. Concordance between adherence
scales was ﬁrst assessed. Using the Morisky-Green score as target
criteria, a segmentation tree was tested in order to forecast
compliance probability. CHAID growing algorithm was used.
RESULTS: A sample of 367 patients was recruited with an
average age of 68 (12.1) years from which 57% were females.
Most patients (87.7%) were diagnosed of glaucoma, 10.5% were
diagnosed of glaucoma and severe PIO and 1.8% presented sever
PIO alone. Agreement between adherence scales was poor with
a marked superiority of the Morisky-Green questionnaire. The
most signiﬁcant segmentation variable was GSS score, followed
by age, glaucoma severity (as assessed by the clinician), number
of treatment drugs, and number treatment of drops. Interaction
was found between number of drops and other variables in the
model. CONCLUSIONS: Using the tree model developed it is
possible to predict compliance probability. Self perceived sym-
ptom discomfort is found to be the best predictor. Additional
evidences of GSS construct validity as a measure of HRQoL have
been found.
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OBJECTIVES: To assess the effect of moderate to severe psoriasis
on quality of life (QoL) in Spanish patients. METHODS: An
observational study was conducted at 132 centers in Spain which
included 10 consecutive patients with moderate to severe psoria-
sis, deﬁned as: 1) patients with Body Surface Area >= 10 or 2)
Psoriasis Area and Severity Index (PASI) >= 10 or 3) Physician’s
Global Assessment >= 5 or 4) patients receiving systemic treat-
ment. Demographic data, medical history, treatments, occupa-
tional impairment, current state of the disease, resource use, and
QoL using the Dermatology Life Quality Index (DLQI) and other
questionnaires were collected. The DLQI is a self-administered
questionnaire with 10 questions measuring 6 domains: symp-
toms and feelings, daily activities, leisure, work and school,
personal relationships and treatment. DLQI results are shown as
mean scores and percentages (mean value obtained over the
maximum score of the domain). RESULTS: A total of 1307
(1141 with complete data) patients with moderate to severe
psoriasis fulﬁlled the inclusion criteria for the present study (38%
female), with a mean age of 45.7  0.9 (mean  SD) years, mean
duration of the disease of 23.3  2.3 years and mean PASI score
of 13.1  0.3. The mean DLQI score was 8.7  0.2, meaning a
moderate effect of psoriasis on patient life. Highest mean scores
(worst) were obtained in symptoms and feelings (2.7, 45%) and
treatment (1.0, 33%) domains and lowest mean scores were
obtained in personal relationships (1.1, 18%) and work and
school (0.7, 23%) domains. Mean scores for daily activities and
leisure were 1.7 (28%) and 1.6 (26%) respectively. CONCLU-
SIONS: Moderate to severe psoriasis has a negative impact on
patient QoL. A more intensive and integrated approach to these
patients should be considered to achieve a smaller impact of
psoriasis on patients’ quality of life.
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OBJECTIVES: To conﬁrm the reliability of quality-of-life (QOL)
assessments in a randomized controlled trial (RCT), we investi-
gated the changes in internal standards as a representative of
‘response shift (RS)’. METHODS: One-hundred and three
patients with age-related maculopathy in Japan were randomized
to the intervention group and the control group. The intervention
group received a standardized low vision care program for 6
months. For ethical considerations, low vision care was also
provided for applicants in the control group after 6 months. We
assessed visual function-related QOL using the Japanese version
of the 25-item National Eye Institute Visual Function Question-
naire (VFQ-25) at baseline, 6-, and 12-months. We asked the
patients to answer an additional questionnaire to investigate the
changes in internal standards at 6- and 12- months which
inquired about QOL at baseline (then-test). This questionnaire
included 7 items selected from the VFQ-25 as the representatives
of major 7 domains (general vision [GV], near vision [NV],
distance vision [DV], social function [SF], mental health [MH],
role limitations [RL], and dependency [DP]). RESULTS: Fifty-
four patients at 6-months and 52 patients at 12-months com-
pleted the then-test questionnaire in addition to the VFQ-25.
Regardless of the direction of change (improved or deteriorated)
in scores, the then-test results tended to decrease the difference
of the scores. That is, then-test scores tended to be higher than
baseline scores in the case of improvement, and tended to be
lower than baseline scores in the case of deterioration. The
statistically signiﬁcant difference was observed between pre- and
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then-test scores only in the item of NV (P < 0.01). This was
consistent in the additional analyses divided into the two RCT
arms on the whole. CONCLUSIONS: The results of this study
suggest that we can rely on the QOL assessment results in RCTs
without worrying too much about RS.
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OBJECTIVES: The objective of this analysis was to examine the
impact of ustekinumab on health related quality of life (HRQoL)
in psoriasis patients. METHODS: 766 patients were enrolled
in the PHOENIX I trial. Patients were randomized to placebo,
ustekinumab 45 mg, or ustekinumab 90 mg. Patients received
ustekinumab at baseline, week 4, and q12w thereafter. Patients
randomized to placebo received placebo at baseline and week 4,
and ustekinumab 45 mg or 90 mg after cross-over at week 12.
HRQoL were assessed using the SF-36 and Dermatology Life
Quality Index (DLQI). RESULTS: Baseline SF-36 and DLQI
scores were similar among treatment groups with a mean PCS
score of 47.9, mean MCS score of 49.8, and mean DLQI score of
11.5. Compared with the placebo group, patients in each usteki-
numab group had signiﬁcantly greater improvements from base-
line in both the PCS (2.0 and 3.2, vs. -0.5, p < 0.001) and MCS
scores (2.1 and 2.5 vs. -1.3, p < 0.001) at week 12. All 8 domains
of the SF-36 showed statistically signiﬁcant improvements
(p < 0.05) in the combined ustekinumab group versus placebo at
week 12. At week 12, themean change from baseline in DLQIwas
-8.0 for the 45 mg group and -8.7 for the 90 mg group versus
-0.6 for the placebo group (each p < 0.001 vs. placebo). A greater
proportion of patients in each ustekinumab group than in the
placebo group achieved a clinically meaningful improvement
in PCS and MCS scores (5-point improvement), and a DLQI
score of 0 or 1 at week 12. These improvements observed in the
ustekinumab groups were maintained through week 40. Patients
in the placebo groupwho crossed-over to ustekinumab at week 12
achieved improvements in PCS, MCS and DLQI scores at week
40 that were similar in magnitude to those observed in patients
initially randomized to ustekinumab. CONCLUSIONS: Usteki-
numab treatment signiﬁcantly improves overall and disease-
speciﬁc quality of life in moderate to severe psoriasis patients.
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OBJECTIVES: To demonstrate the pertinence of using thermal
therapy in terms of quality of life. METHODS: During the 2005
and 2006 seasons, a generic scale (SF-12) and a speciﬁc scale
(DLQI—Dermatology Life Quality Index) were ﬁlled in by each
patient when they arrived at the Avène hydrotherapy center
(consultation on arrival), at the end of the thermal therapy (week
3), but also at 3 and 6 months after the end of the therapy.
RESULTS:These results took into account the 262 questionnaires
from patients suffering from psoriasis who ﬁlled in the self-
questionnaires on arrival. The average age of the subjects was
52.2  13.8 years. The gender ratio was in favour of men (55.3%
vs 44.7%). The average age of the subjects at the time of diagnosis
was 32.1  16.9 years. 66.0% of the subjects considered that
their dermatosis had deteriorated “their daily life”, 49.6% “their
health” and 49.2% “their leisure activities”. Following the 3
weeks of treatment these feelings had strongly diminished, there
were respectively only 35.2%, 26.6%and 30.5%who thought so.
The DLQI score on arrival was 26.1  20.2; following therapy
it was 10.0  10.5. The evaluation of the DLQI score was com-
pared to the score obtained on arrival, showing a signiﬁcant
improvement in quality of life at 3 weeks, sustained improvement
at 3 months and perpetuation of the effect at 6 months (p < 0.05).
These results showa signiﬁcant improvement in themental dimen-
sion of the SF-12 (MCS-12 = 39.0 on arrival to 42.5 at following
therapy). CONCLUSIONS: This study conﬁrms the alteration in
the quality of life of patients suffering frompsoriasis and its impact
on daily life. The results conﬁrm the improvement in the patients’
quality of life following the therapy, sustained improvement at 3
months, and perpetuation at 6 months.
PSS43
ATOPIC DERMATITIS ANDTHERMALTHERAPY: EVALUATION
OF MEDICAL SERVICE
Boussetta S1,Taieb C2
1Pierre Fabre, Boulogne, France, 2Pierre Fabre, Boulogne, FRANCE,
France
OBJECTIVES: To demonstrate the pertinence of using thermal
therapy in terms of quality of life. METHODS: During the 2005
and 2006 seasons, a generic scale (SF-12) and a speciﬁc scale
(DLQI—Dermatology Life Quality Index) were ﬁlled in by each
patient when they arrived at the Avène hydrotherapy center
(consultation on arrival), at the end of the thermal therapy (week
3), but also at 3 and 6 months after the end of the therapy.
RESULTS: These initial results took into account the 174 ques-
tionnaires from patients suffering from atopic dermatitis. The
average age of the subjects was 36.4  14.7 years. The gender
ratio was largely in favour of women (70.1% vs 29.9%). The
median age of the subjects at the time of diagnosis was 16.0
years. Women were diagnosed earlier than men, with a median
diagnosis age of 8.0 years for women and 20 years for men.
72.1% of subjects considered that their dermatosis had deterio-
rated “their daily life”, 58.9% “their health” and 60.0% “their
leisure”. Following the 3 weeks of therapy these feelings had
strongly diminished, and respectively only 44.3%, 34.8% and
35.3% thought so. The DLQI score on arrival was 32.4  22.7
The evaluation of the DLQI score was compared to the DLQI
score obtained on arrival, showing a signiﬁcant improvement in
quality of life at 3 weeks sustained improvement at 3 months and
perpetuation of the effect at 6 months. No signiﬁcant improve-
ment in either the mental dimension or the physical dimension of
the SF-12 were observed. CONCLUSIONS: This study conﬁrms
the alteration in the quality of life of patients suffering from
atopic dermatitis and its impact on daily life. The results conﬁrm
the improvement in the patients’ quality of life following the
therapy, sustained improvement at three months, and perpetua-
tion at six months.
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OBJECTIVES: The objective of this project was to conduct a
cross-evaluation of the quality of life of patients suffering from
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